© Reuters.
On Monday, BTIG initiated coverage on biotechnology company AnaptysBio (NASDAQ:), which is listed on NASDAQ:ANAB, with a Buy rating and a price target set at $55.00 highlighting the company’s innovative approach in autoimmune diseases.
“Checkpoint agonism in autoimmune disease remains underexplored and ANAB is pursuing this broad opportunity with PD-1 and BTLA agonists that are well-positioned to emerge as best-in-class”, says BTIG analyst.
The coverage notes that despite previous safety concerns regarding checkpoint agonism due to its use in cancer treatments, a thorough review of biological data and existing datasets indicates that these concerns may be overstated. This presents an opportunity for investors to engage with an underexplored area of autoimmune treatment.
BTIG is closely monitoring Eli Lilly (NYSE:)’s PD-1 agonist peresolimab, particularly in relation to rheumatoid arthritis, the largest market for inflammation and immunology (I&I) worldwide. The firm anticipates that forthcoming Phase 2b data will reaffirm the efficacy shown in Phase 2a trials. A positive outcome could significantly benefit AnaptysBio’s stock, potentially by more than 75%. While the timing of these developments remains uncertain, directional clarity is expected in 2024.
In the scenario where peresolimab encounters adverse results, BTIG estimates that the downside risk for AnaptysBio’s stock would be limited to a 20-40% decrease. This is due to the company’s robust cash position and anticipated Phase 2 atopic dermatitis data by the end of 2024.
BTIG also points out that AnaptysBio’s rosnilimab holds several pharmacodynamic advantages over peresolimab, which may result in an asymmetric risk/reward balance favoring AnaptysBio ahead of potential catalysts from Eli Lilly.
Furthermore, BTIG expresses interest in AnaptysBio’s BTLA agonist, ANB032, due to its potential to address inflammation in atopic dermatitis more comprehensively. This market is expected to triple the size of the psoriasis market at maturity. As dissatisfaction with current standard of care treatments persists, with less than 25% of atopic dermatitis patients fully satisfied, there is an increasing openness to new mechanisms of action.
AnaptysBio is expected to release Phase 2b data on ANB023 in atopic dermatitis by the end of 2024, which could strengthen the company’s stock leading up to the data release.
InvestingPro Insights
As BTIG initiates coverage on AnaptysBio with a bullish outlook, real-time data and insights from InvestingPro provide additional context for investors considering the company’s prospects. AnaptysBio has shown a significant 233.18% revenue growth over the last twelve months as of Q1 2023, indicating a strong upward trajectory in its financial performance. This growth is further exemplified by an impressive 81.04% three-month price total return, suggesting a positive reception in the market to the company’s recent developments.
InvestingPro Tips highlight that AnaptysBio is trading near its 52-week high, with the stock price at 99.04% of this peak. This could reflect the market’s confidence in the company’s innovative approach to autoimmune diseases. Moreover, with management’s strategy of share buybacks and a balance sheet that holds more cash than debt, AnaptysBio appears to be in a solid financial position. It’s important to note that while analysts do not anticipate the company to be profitable this year, AnaptysBio’s liquid assets exceed its short-term obligations, providing some financial stability.
For those interested in a deeper analysis, InvestingPro offers additional insights into AnaptysBio’s performance and projections. There are currently 13 more InvestingPro Tips available for AnaptysBio, which can be accessed by visiting: https://www.investing.com/pro/ANAB. To enrich your investment research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
